NGS Sample Preparation Market- Growth, Trends, Covid-19 Impact, and Forecasts (2022 - 2027)

NGS Sample Preparation Market- Growth, Trends, Covid-19 Impact, and Forecasts (2022 - 2027)

The next-generation sequencing (NGS) sample preparation market is projected to register a CAGR of 12.4% during the forecast period (2022-2027).

The outbreak of the COVID-19 pandemic has pushed the pharmaceutical industry into action, with a race to develop both therapeutic and preventive interventions. The increasing cases of the coronavirus worldwide led to the need to develop effective and quick sequencing technologies to rebuild the genomic sequence of SARS-CoV-2, which was the etiological agent of COVID-19. It was critical in the development of diagnostic molecular tests as well as the development of efficient tactics and strategies to slow the spread of the pandemic. For instance, in August 2020, Helix Laboratory received the United States Food and Drug Administration emergency use authorization for NGS based COVID-19 test, which is designed to detect the SARS-CoV-2 spike protein gene in the upper respiratory specimens. Thus, the NGS sample preparation market is expected to be positively impacted by COVID-19.

Furthermore, according to the estimates of the World Health Organization in 2022, about 555,446,890 cases were confirmed all over the world for COVID-19. This next-generation sequencing was applied to study COVID-19 and has greatly promoted SARS-CoV-2 original tracking. The novel coronavirus SARS-CoV-2 has caused a highly transmissible and ongoing pandemic worldwide. Due to its rapid development, next-generation sequencing (NGS) sample preparation plays a vital role in many aspects.

In addition, the rising prevalence of infectious diseases, reduced cost of sequencing, and technical advancement in NGS platforms are actively affecting the growth of the studied market.

With the increasing prevalence of infectious diseases, NGS sequencing technologies have swiftly become the method of choice in virology for a wide range of applications, including the detection of novel viruses from metagenomic samples, reconstruction of whole or almost complete viral genome sequences, and viral evolution and subspecies analysis. For instance, the World Health Organization (WHO) August 2022 Influenza Update, stated that National Influenza Centers (NICs) and other national influenza laboratories from 120 countries, regions, or territories submitted data to FluNet for the time period from 11 July 2022 to 24 July 2022. Over 145,086 samples were analyzed by the WHO Global Influenza Surveillance and Response System (GISRS) laboratories during that time. Among the 6,449 people who tested positive for influenza viruses, 97.7% had influenza A and 2.3% had influenza B.

NGS technologies have replaced the traditional sequencing methods because of the low cost and high efficiency of sequencing. For instance, according to Illumina in 2021, since the completion of the Human Genome Project, the cost of next-generation sequencing (NGS) has decreased at a dramatic rate. Illumina has helped reduce the cost of NGS, enabling the USD 1000 human genome. Hence, these advantages possessed by NGS sample preparation are expected to boost the demand for NGS sample preparation.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period. However, the high costs of NGS sample preparation equipment and strict regulation associated with NGS Sample preparation are likely to impede the market growth.

Key Market TrendsDiagnostics Segment is Expected to Dominate the Market Over the Forecast Period

The research and treatment of cancer have been transformed by next-generation sequencing (NGS) as sequencing of individual cancer‐patient genomes has been carried out using NGS base genomic sequencing and it has become faster and less expensive with each passing year, allowing NGS to be utilized not just in research but also in clinical practice. For instance, in August 2020, the European Society for Medical Oncology (ESMO), the professional organization for medical oncology launched its first recommendations on the use of next-generation sequencing (NGS) for patients with metastatic cancers. According to ESMO recommendations, in colon cancers, NGS could be an alternative to Polymerase Chain Reaction (PCR). NGS can be suitable for the identification of multiple genes and their mutations concurrently by sequencing millions of DNA reads and driving therapeutic decision-making. This is projected to increase in adoption of next-generation sequencing sample preparation for drug development.

Another factor that is driving the market for NGS sample preparation is the increased number of genomic research projects globally. For instance, in June 2020, the United States Food and Drug Administration (USFDA) issued an emergency use authorization (EUA) to Illumina Inc. for the first COVID-19 diagnostic test utilizing next-generation sequence technology. The FDA authorized the Illumina COVIDSeq Test for the qualitative detection of SARS-CoV-2 RNA. Thus, NGS plays an important role in the diagnosis and monitoring of various infectious diseases, which may fuel market growth.

​Additionally, the advancements in technology and increasing product approvals and launches along with partnerships and collaborations by key players are helping in the market growth. For instance, in February 2021, QIAGEN and INOVIO expanded their partnership to create a companion diagnostic using next-generation sequencing (NGS) for INOVIO’s VGX-3100 for advanced cervical dysplasia. These partnerships are likely to increase the demand for next-generation sequencing for diagnostic purposes in recent years.

Furthermore, in Aug 2020, Guardant Health Inc. received the United States Food and Drug Administration (FDA) approval for Guardant360 CDx, which uses two combined technology, Liquid biopsy, and NGS in one diagnostic test. Hence, the increasing product approval related to NGS diagnostic for COVID-19 is projected in the surge of growth of the studied market.

Therefore, these factors are expected to propel the growth of the diagnostics segment in the studied period.

North America is Expected to Dominate the NGS Sample Preparation Market.

North America is expected to dominate the market owing to factors such as the rising need for diagnostics tools for identifying health disparities, awareness among people and healthcare industry stakeholders about available technologies, the high concentration of market players in the United States, and the rising burden of infectious diseases and chronic diseases in the region.

The increasing technological advancement, product launches, partnerships, and acquisitions by the key market players are leading to an increase in the market growth in North America. For instance, in January 2022, Illumina Inc. and Nashville Biosciences LLC, a subsidiary of Vanderbilt University Medical Center (VUMC), entered a multi-year agreement to accelerate medicines development through large-scale genomics and the establishment of a clinical-genomic resource using Illumina's next-generation sequencing (NGS) platforms. Such partnerships are expected to drive the growth of the NGS sample preparation market in North America.

Also, in April 2021, Resolution Bioscience, a leader in the research and commercialization of next-generation sequencing (NGS)-based precision oncology solutions, has been acquired by Agilent Technologies. These acquisitions are likely to boost the growth of the studied market in the country.

Furthermore, increased funding from the federal government and private players, as well as increased adoption of NGS technology by non-government and government bodies, are expected to drive market growth. For instance, in January 2020, in the United States, the Intelligence Advanced Research Projects Activity provided USD 23 million to the Broad Institute and Harvard University, and DNA Script. The organizations have been working together to explore the possibility of combining the enzymatic DNA synthesis technology and NGS into a single instrument for more than four years. Such developments are a major boost to the clinical studies and organizations progressing with NGS as their basis of innovation.

Therefore, owing to the above-mentioned factors, the growth of the studied market is anticipated in the North America Region.

Competitive Landscape

The NGS sample preparation market is slightly consolidated in nature due to the presence of some companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known. Illumina, Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Qiagen N.V., PerkinElmer Inc., F.Hoffmann-La Roche Ltd, BGI Genomics, DNASTAR, Eurofins Scientific, Danaher Corporation (Beckman Coulter), Macrogen Inc., Integrated DNA Technologies, Inc. (Swift Biosciences Inc.), Genomatix, Helix OpCo, LLC are among important key players.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.